Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Avricore Health Inc AVCRF


Primary Symbol: V.AVCR

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Post by lscfaon Nov 18, 2024 9:26pm
68 Views
Post# 36319027

Forecast

Forecast

Co. says it will better off a year from now. Assuming more testing in the UK than Canada due to govt. reimbursement  2025 revenues will exceed 2024 revenues even with the redeployment of fewer devices by year end 2025.

 

 

Qtr ending

Deployed

Lease & service

Products sold

Revenue

Q4 25 (e)

500

375,000

1,500,000

1,875,000

Q3 25 (e)

300

225,000

900,000

1,125,000

Q2 25 (e) 

100

75,000

300,000

375,000

Q1 25 (e) 

300

225,000

300,000

525,000

Q4 24 (e)

800

600,000

400,000

1,000,000

Q3 24 (e)

800

600,000

400,000

1,000,000

Q2 24

781

581,166

464,040

1,045,206

Q1 24

775

563,487

560,820

1,124,307

Q4 23

693

475,579

878,824

1,354,403

Q3 23

635

406,119

547,335

953,454

Q2 23

541

387,206

160,843

548,049

Q1 23

532

311,001

318,240

629,241

Q4 22

416

140,685

836,550

977,235

Q3 22

166

52,290

519,938

572,228

Q2 22

53

14,940

161,235

176,175

Q1 22

53

14,491

28,245

42,736

Q4 21

20

0

35,190

35,190

 

<< Previous
Bullboard Posts
Next >>